A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients
Latest Information Update: 02 Jun 2021
At a glance
- Drugs ISN 001 (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Sponsors Ishin Pharmaceutical
- 31 May 2021 Status changed from recruiting to completed.
- 31 Jul 2017 New trial record